AzTrials
AzTrials

Turner SyndromeSEXATURNNCT05223621

Sexuality and Sexual Quality of Life in Adult Patients With Turner Syndrome (TS) Compared With Patients With Primary Ovarian Insufficiency Different From TS

An observational study of Turner Syndrome and Primary Ovarian Insufficiency, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Turner syndrome (TS) is a rare disease affecting 1/2500 female. It is defined by a complete or partial loss of an X chromosome associated with clinical signs. The most frequent signs are a small height and primary ovarian insufficiency (POI). POI occurs in 95% of patients with TS. Read more about this study

Who is it for?
Ages 18 to 50 years, women only
How many people
300 participants
Where
1 siteFrance
Study dates
Feb 2022to May 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Patients followed in our reference center of rare diseases named CMERCD belonging to FIRENDO network of rare diseases in France ; our center is labelled as an endo-ERN center of rare diseases.

Who may be able to join

  • karyotype with at least10% of 45,X cells
  • age between 18-50
  • followed in our reference centre

Who cannot join

  • refusal of patients to participate
  • Without health insurance
  • Patients under supervision \& guardianship

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital St Antoine, Sorbonne University, Endocrinology-Diabetology Department, Reproductive medicine

    Paris, 75012

Other trials in France

About this study

Official title: Sexuality and Sexual Quality of Life in Adult Patients With Turner Syndrome (TS) Compared With Patients With Primary Ovarian Insufficiency and Normal Karyotype

Turner syndrome (TS) is a rare disease affecting 1/2500 female. It is defined by a complete or partial loss of an X chromosome associated with clinical signs. The most frequent signs are a small height and primary ovarian insufficiency (POI). POI occurs in 95% of patients with TS. Clinically, patients have amenorrhea with elevated FSH levels (> 25 IU/L), before the age of 40. In most cases, patients receive hormonal replacement therapy. Among patients with POI, TS is present in less than 10% of cases. Therefore POI may occur in patients with normal karyotype, therefore without TS.

Preliminary data suggest altered sexual function in patients with TS. The first goal of our study is to evaluate sexual function and sexual quality in patients with TS using a questionnaire, the Female Sexual Function Index (FSFI).

Read more

The second goal is to compare sexual quality in patients in patients with TS compared to female patients with POI not related to TS. Our study should identify predictive markers of altered sexual function.

The final endpoint is to optimize the quality of life of patients with TS and to enhance, if necessary psychological support in such patients.

Read the detailed description

Turner syndrome (TS) is a rare disease. It affects around 1/2500 female newborns. It is defined as a chromosomal abnormality with a total or partial loss of one X chromosome associated with clinical signs of TS, such as a small height and primary ovarian insufficiency (POI). POI is present in 95% of patients with TS. Its definition relies on amenorrhea or severe oligomenorrhea with an elevated FSH level higher than 25 IU/L occurring before the age of 40 years. In TS, POI is related to an accelerated ovarian follicle loss due to atresia. Patients with POI should receive hormonal replacement therapy (HRT) with estrogen and progesterone/progestin. Patients with POI should be on HRT until the age of physiological menopause, around 51 years of age. One of the main consequence of POI is infertility. The rate of natural pregnancy in women with TS is around 7%. Other clinical signs included in TS are cardiovascular diseases (50% of cases), deafness (34%), renal diseases (24-42%) or autoimmune diseases. Recent studies suggest psychological abnormalities in patients with TS. They include low self-esteem, anxiety and in some cases autistic traits. Preliminary studies have suggested altered sexual life in women with TS. The goal of our study is to evaluate the quality of sexual life in such patients using of validated questionnaire, the Female Sexual Fonction Index (FSFI).

This questionnaire contains 19 questions. It has been translated in French. It has been previously used in a French study testing sexual life of women with 21 hydroxylase deficiency. Recently a simplified version of this questionnaire containing only 6 questions has been validated. Several studies using both questionnaires have shown similar results with both questionnaire. Therefore, the investigators are going to use the simplified questionnaire. A major reason is that patients with TS have in general a low self-esteem and the simplified version is less intrusive than the entire questionnaire. Therefore , the investigators believe that it will be easier for patients with TS to fill this simplified version of FSFI questionnaire.

In order to evaluate whether sexual dysfunction in women with TS is related to Turner syndrome or to POI by itself, the investigators have included a control group. Women with POI with normal karyotype, in whom POI is not related to Turner syndrome are going to be included in our study. POI in such women may be related to chemotherapy, radiotherapy, ovarian surgery, autoimmune diseases or genetic diseases. So far, more than 70 candidate genes have been identified in patients with POI.

Our Unit, based in St Antoine hospital, Assistance-Publique hôpitaux de Paris, France, has been recognized in 2006 by the French Ministry of Health as a reference center for rare endocrine diseases including Turner syndrome and patients with POI. Our center belongs to FIRENDO network and is recognized as a member of the European network of rare diseases (Endo-ERN). It includes 350 patients with TS and 600 patients with POI not related to TS. All patients have given an authorization to use their clinical data. In order to have a high rate of responders , the investigators are going to send the questionnaire to patients who last visited our Unit between 2018 and December of 2020.

The main goal of our study is to evaluate sexual function of such patients and , the investigators wish to confirm or not whether sexual quality of sexual life is altered in patients with TS. If our study illustrates such an alteration, special care concerning sexual function should be initiated in patients with TS. In particular, psychologists should be recruited to improve the life of patients with TS. Our study should have a direct impact in patients with TS.

Two groups of adult patients, aged between 18 and 50 years of age, are going to receive the simplified FSFI anonymous questionnaire by postal mail. The first group is women with POI related to TS and the second group women with POI not related to TS. If no answer is received, patients will be called over the phone by a single physician in order to help the patients answer the questionnaire (Dr Emma Dubost).

Keywords
Sexual life, sexuality, Turner syndrome, primary ovarian insufficiency
Medical subject headings
Turner Syndrome, Primary Ovarian Insufficiency, Sexuality

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05223621
Study groupRoleWhat they receive
Turnerpatients with Turner syndrome
POIpatients with primary ovarian failure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sexuality anomalies with score (patient TS)

    Measuring sexuality anomalies thanks to FSFI-6 questionnaire by TS patients the day of inclusion (score between " 30 " corresponding to " no sexual abnormalities " and " 0 " corresponding to " maximum sexual abnormalities signs ".

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2022
  2. Study startFeb 2022 (estimated)
  3. Primary completionMay 2022 (estimated)
  4. Study completionMay 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05223621
Sponsor's protocol ID
APHP200833
Other IDs
IDRCB 2020-A01768-31
Acronym
SEXATURN
Status last verified
Jan 2022
First submitted
31 Jul 2021
Last updated
4 Feb 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • de Paillette E, Karila D, Rousseau A, Dubost E, Meykiechel T, Lamothe S, Vatier C, Jaillard S, Nedelcu M, Bourcigaux N, Donadille B, Christin-Maitre S. SEXATURN: sexual function of patients with Turner syndrome compared to that of women with premature ovarian insufficiency. Sex Med. 2026 Aug 17;14(5):qfag074. doi: 10.1093/sexmed/qfag074. eCollection 2026 Oct.

    PubMed 42610070

Questions about this trial

What is this clinical trial studying?

An observational study of Turner Syndrome and Primary Ovarian Insufficiency, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sexuality anomalies with score (patient TS) (time frame: Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05223621, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in